日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

ALK重排伴获得性ETV6-NTRK3融合的肺腺癌患者接受五线治疗后，对布加替尼联合恩曲替尼治疗反应迅速：病例报告

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2024.1339511
Li, Dan; Zhu, Yue; Song, Jincheng; Yang, Dafu; Cui, Saiqiong; Liu, Xin; Wang, Le; Zhang, Jiangyan; Pan, Evenki; Dai, Zhaoxia
ALK
肿瘤
NTRK3
肿瘤免疫
发表日期：2024
文献求助 收藏

A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review

一例携带种系EGFR R776H突变的原发性肺癌和乳腺癌患者：病例报告及文献综述

期刊:Oncotargets and Therapy
影响因子:2.8
doi:10.2147/OTT.S391766
Li, Dan; Liu, Xin; Cui, SaiQiong; Yang, DaFu; Zhu, Yue; Pan, Evenki; Yang, Peng; Dai, ZhaoXia
肺癌
肿瘤
肿瘤免疫
EGF
乳腺癌
EGFR
发表日期：2023
文献求助 收藏

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors

携带新型ALK融合变异的肺腺癌患者及其对ALK抑制剂的临床反应

期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12128
Yang, Dafu; Li, Dan; Dai, Zhaoxia; Ma, Yutong; Ou, Qiuxiang; Wu, Xue; Cui, Saiqiong
ALK
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma

EGFR突变型肺腺癌患者二线奥希替尼耐药后基于NGS的ctDNA分析

期刊:Oncotargets and Therapy
影响因子:2.8
doi:10.2147/OTT.S318250
Li, Dan; Yang, DaFu; Cui, SaiQiong; Pan, Evenki; Yang, Peng; Dai, ZhaoXia
EGFR
肿瘤
EGF
肿瘤免疫
发表日期：2021
文献求助 收藏

[Clinical Value of Cerebrospinal Fluid ctDNA in Patients 
with Non-small Cell Lung Cancer Meningeal Metastasis].

[脑脊液ctDNA在非小细胞肺癌脑膜转移患者中的临床价值]

期刊:Chinese Journal of Lung Cancer
影响因子:
doi:10.3779/j.issn.1009-3419.2020.102.42
Zhang Kunyu, Dai Zhaoxia, Liu Siya, Li Dan, Yang Dafu, Cui Saiqiong
细胞生物学
肺癌
肿瘤免疫
发表日期：2020
文献求助 收藏